ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 15 for:    "cystinuria"

This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03539926
Recruitment Status : Recruiting
First Posted : May 30, 2018
Last Update Posted : June 13, 2018
Sponsor:
Collaborators:
Clever Instruments S.L.
Fundacio Puigvert
Information provided by (Responsible Party):
Devicare S.L.

Brief Summary:
This study evaluates the superiority of daily self-pH monitorization of Lit-control®pH meter compared to the monitorization of reactive strips (standard of care).

Condition or disease Intervention/treatment Phase
Cystinuria Device: Lit-control®pH Meter Diagnostic Test: Reactive strips Not Applicable

Detailed Description:

Cystinuria is a disease of autosomal recessive inheritance. This disease belongs to the so-called orphan diseases although its prevalence may change depending on the country.

It is known that urinary pH is a risk factor for the formation of cystine crystals because their solubility is pH-dependent. In different studies it has been shown that the solubility of cystine in urine increases when alkalinizing urinary pH, thus reducing the likelihood of crystal formation. Therefore, the control of urinary pH along with hygienic-dietetic measures that alkalize the urine or decrease the urinary concentration of cystine (abundant intake of water, food, etc.) are highly recommended as a preventive method to prevent the formation of cystine crystals whose retention and growth results in the formation of stones.

The Lit-control®pH Meter is a pH meter that allows a patient to self-monitor its urinary pH in a comfortable and simple way. With this tool the patient is able to know if his urinary pH is within the recommended limits. In other medical fields it has been observed that home monitoring of clinically relevant physiological parameters is a way of empowering the patient that can positively affect their attitudes and behaviors (adherence to received treatment, quality of life) and potentially improve their medical condition. Specifically, in patients with chronic diseases, the self-monitoring has been associated with a significant reduction in hospitalizations and hospital readmissions.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Patients will receive the product for home pH monitoring, but they will keep following the doctor's recommendations indicated in the usual clinical practice.

The proportion of patients will be 1: 1 between the study group (Lit-control®pH Meter) and the control group (test strips).

Masking: None (Open Label)
Masking Description: The process of randomization, either device use or use of strips, will be masked until the moment it is delivered to the patient. The random assignment to each product will be made through lists created by an ad hoc computer program.
Primary Purpose: Other
Official Title: Randomized, Controlled and Opened Trial on the Impact of the Use of a pH-Meter on the Domiciliary Control of the Urinary pH as Adjuvant to the Treatment of Cystinuric Patients
Actual Study Start Date : April 9, 2018
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lit-control®pH Meter
The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
Device: Lit-control®pH Meter
Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.

Placebo Comparator: Reactive strips
The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
Diagnostic Test: Reactive strips
Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.




Primary Outcome Measures :
  1. Percentage of days with pH levels within range 7 and 8, during 6 months of home self-monitoring. [ Time Frame: 183 measurements (morning) in 6 months. ]
    Urinary pH measurement

  2. Percentage of days with pH levels within range 7 and 8, during 6 months of home self-monitoring. [ Time Frame: 183 measurements (afternoon) in 6 months. ]
    Urinary pH measurement

  3. Measurement of the volume of crystalluria. [ Time Frame: 1 measurement at the moment of enrollment ]
    volume of crystalluria

  4. Measurement of the volume of crystalluria. [ Time Frame: 1 measurement at 6 months ]
    volume of crystalluria

  5. Blood: DNA extraction. [ Time Frame: 1 measurement at the moment of enrollment ]
    Extraction of DNA for genetic study of mutations for cystinuria.

  6. Sediment analysis for the determination of urinary infection. [ Time Frame: 1 measurement at the moment of enrollment ]
    Sediment analysis for the determination of Ulcer Index (UI)

  7. Sediment analysis for the determination of urinary infection. [ Time Frame: 1 measurement at 6 months ]
    Sediment analysis for the determination of UI

  8. Total time within the margins established as safe in the pH control (months). [ Time Frame: 1 measurement through study completion [up to 6 months] ]
    Amount of time within the pH margins established as safe

  9. Adherence level in pH measurements [ Time Frame: Through study completion, fraction of pH measurements on the total possible. [up to 6 months] ]
    % compliance of the pH measurements

  10. Adherence level to treatment [ Time Frame: Through study completion, fraction of intakes on the total possible. [up to 6 months] ]
    % of the intakes of the medication.

  11. Total number of adverse events reported. [ Time Frame: Through study completion, number of events. [up to 6 months] ]
    Amount of adverse events reported

  12. Blood Analysis. Glucose [ Time Frame: Change from Baseline measurement at 6 months ]
    Glucose in mmol/L

  13. Blood Analysis. Calcium phosphate [ Time Frame: Change from Baseline measurement at 6 months ]
    calcium phosphate in µmol/L

  14. Blood Analysis. Estimated Glomolecular Filtration Chronic Kidney Disease Epidemiology Collaboration (FG CKD-EPI) [ Time Frame: Change from Baseline measurement at 6 months ]
    estimated FG CKD-EPI

  15. Blood Analysis. Cystatin [ Time Frame: Change from Baseline measurement at 6 months ]
    cystatin in mg/L (to be measured only if estimated FG> 45 or <ml /min / 1.73 m2 and albumin / creatinine in the urine <3 mg / mmol)

  16. Blood Analysis. Creatinine [ Time Frame: Change from Baseline measurement at 6 months ]
    creatinine in µmol/L

  17. Blood Analysis. Urate [ Time Frame: Change from Baseline measurement at 6 months ]
    urate in μmol/L

  18. 24h Urine Analysis. Weight [ Time Frame: Change from Baseline measurement at 6 months ]
    Weight in kg

  19. 24h Urine Analysis. Size [ Time Frame: Change from Baseline measurement at 6 months ]
    Size in m

  20. 24h Urine Analysis. Urinary volume [ Time Frame: Change from Baseline measurement at 6 months ]
    Urinary volume in L

  21. 24h Urine Analysis. Calcium phosphate [ Time Frame: Change from Baseline measurement at 6 months ]
    calcium phosphate in µmol/L

  22. 24h Urine Analysis. Citrate [ Time Frame: Change from Baseline measurement at 6 months ]
    citrate in μmol/L

  23. 24h Urine Analysis. Urate [ Time Frame: Change from Baseline measurement at 6 months ]
    urate in μmol/L

  24. 24h Urine Analysis. Magnesium [ Time Frame: Change from Baseline measurement at 6 months ]
    magnesium in μmol/L

  25. 24h Urine Analysis. Sodium [ Time Frame: Change from Baseline measurement at 6 months ]
    sodium in μmol/L

  26. 24h Urine Analysis. BMI [ Time Frame: Change from Baseline measurement at 6 months ]
    weight and height will be combined to report BMI in kg/m^2

  27. 24h Urine Analysis. Potassium [ Time Frame: Change from Baseline measurement at 6 months ]
    potassium in μmol/L

  28. 24h Urine Analysis. Urea [ Time Frame: Change from Baseline measurement at 6 months ]
    urea in µmol/L

  29. Urine for the study of crystalluria. Schedule [ Time Frame: Change from Baseline measurement at 6 months ]
    First urine of the morning (totality) for the study of crystalluria. Patient will provide the last hour of urination and hour of urine obtention in the morning.

  30. Urine for the study of crystalluria. Crystalline volume [ Time Frame: Change from Baseline measurement at 6 months ]
    overall crystalline volume (μm3 / mL)

  31. Urine for the study of crystalluria. Crystals [ Time Frame: Change from Baseline measurement at 6 months ]
    type and number of crystals (crystals / μL)

  32. Urine for the study of crystalluria. Urine volume [ Time Frame: Change from Baseline measurement at 6 months ]
    urine volume in L

  33. Urine for the study of crystalluria. pH [ Time Frame: Change from Baseline measurement at 6 months ]
    pH

  34. Urine for the study of crystalluria. Size [ Time Frame: Change from Baseline measurement at 6 months ]
    size in μm

  35. Urine for the study of crystalluria. Density [ Time Frame: Change from Baseline measurement at 6 months ]
    Density in mg / mL.

  36. Urine for the study of crystalluria. Aggregation [ Time Frame: Change from Baseline measurement at 6 months ]
    aggregation

  37. Urine for the study of crystalluria. Twinning [ Time Frame: Change from Baseline measurement at 6 months ]
    twinning

  38. Urine for the study of crystalluria. Quotient [ Time Frame: Change from Baseline measurement at 6 months ]
    Quotient albumin / creatinine


Secondary Outcome Measures :
  1. Sociodemographic and anthropometric questionnaire. [ Time Frame: 1 day of enrollment ]
    Family and personal background and general data (sex, age, etc.).

  2. Patient satisfaction questionnaire with the pH measurement method [ Time Frame: 3 times in 6 months ]
    Visual Analogue Scale ranging from 1 (very dissatisfied) to 10 (very satisfied)

  3. Physician satisfaction questionnaire with the pH measurement method [ Time Frame: 3 times in 6 months ]
    Likert Scale with 4 categories: very dissatisfied, dissatisfied, satisfied, very satisfied



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years old.
  • Cystinuric patients, with or without urinary lithiasis at the time of inclusion.
  • Patients who accept their participation in the study and give their informed consent.

Exclusion Criteria:

  • Patients with pathologies that require pH control other than the one established in the study protocol to avoid the formation of kidney stones.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03539926


Contacts
Contact: Oriol Angerri, MD 934 16 97 00 oangerri@fundacio-puigvert.es

Locations
Spain
Fundacio Puigvert Recruiting
Barcelona, Spain, 08025
Contact: Oriol Angerri, MD    934 16 97 00    oangerri@fundacio-puigvert.es   
Sub-Investigator: Sílvia Gràcia, MD         
Sub-Investigator: Ferran Rousaud, MD         
Sponsors and Collaborators
Devicare S.L.
Clever Instruments S.L.
Fundacio Puigvert
Investigators
Principal Investigator: Oriol Angerri, MD Fundacio Puigvert

Responsible Party: Devicare S.L.
ClinicalTrials.gov Identifier: NCT03539926     History of Changes
Other Study ID Numbers: DEV-LCD-01-17
First Posted: May 30, 2018    Key Record Dates
Last Update Posted: June 13, 2018
Last Verified: June 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Devicare S.L.:
Cystinuria
pH Control

Additional relevant MeSH terms:
Cystinuria
Renal Aminoacidurias
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases